专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07300920B2 Antiangiogenic peptide agents 失效
标题翻译：抗血管生成肽剂
公开(公告)号：US07300920B2
公开(公告)日：2007-11-27
申请号：US10714067
申请日：2003-11-14
申请人： Richard I. Weiner , Joseph A. Martial , Ingrid Struman , Robert Taylor , Frauke Bentzien
发明人： Richard I. Weiner , Joseph A. Martial , Ingrid Struman , Robert Taylor , Frauke Bentzien
IPC分类号： A61K38/18 , A61K31/27 , C07K14/475 , C07K14/61
CPC分类号： C07K14/57554 , A61K38/00 , C07K14/57518 , C07K14/61
摘要： The current invention provides novel antiangiogenic peptides which correspond to about 133 consecutive amino acids of the N-terminal sequence of growth hormone.
摘要翻译：本发明提供对应于生长激素的N-末端序列的约133个连续氨基酸的新型抗血管生成肽。

2. 发明申请

US20080096795A1 Novel Antiangiogenic Peptide Agents and Their Therapeutic and Diagnostic Use 审中-公开
公开(公告)号：US20080096795A1
公开(公告)日：2008-04-24
申请号：US11875323
申请日：2007-10-19
申请人： Richard Weiner , Joseph Martial , Ingrid Struman , Robert Taylor , Frauke Bentzien
发明人： Richard Weiner , Joseph Martial , Ingrid Struman , Robert Taylor , Frauke Bentzien
IPC分类号： A61K38/00 , A61P43/00 , C07K16/00
CPC分类号： C07K14/57554 , A61K38/00 , C07K14/57518 , C07K14/61
摘要： The current invention concerns novel antiangiogenic peptides which correspond to about 10 to about 150 consecutive amino acids of N-terminal sequences of human growth hormone, human placental lactogen, human growth hormone variant hGH-V, and prolactin, and their use in inhibiting angiogenesis and in the diagnosis of diseases of human pregnancy involving abnormalities of placental vascularization.

3. 发明申请

US20080090750A1 Novel Antiangiogenic Peptide Agents and Their Therapeutic and Diagnostic Use 审中-公开
标题翻译：新型抗血管生成肽剂及其治疗和诊断用途
公开(公告)号：US20080090750A1
公开(公告)日：2008-04-17
申请号：US11875308
申请日：2007-10-19
申请人： Richard Weiner , Joseph Martial , Ingrid Struman , Robert Taylor , Frauke Bentzien
发明人： Richard Weiner , Joseph Martial , Ingrid Struman , Robert Taylor , Frauke Bentzien
IPC分类号： A61K38/00 , A61P43/00 , C07K16/00
CPC分类号： C07K14/57554 , A61K38/00 , C07K14/57518 , C07K14/61
摘要： The current invention concerns novel antiangiogenic peptides which correspond to about 10 to about 150 consecutive amino acids of N-terminal sequences of human growth hormone, human placental lactogen, human growth hormone variant hGH-V, and prolactin, and their use in inhibiting angiogenesis and in the diagnosis of diseases of human pregnancy involving abnormalities of placental vascularization.
摘要翻译：本发明涉及对应于人生长激素，人胎盘乳腺癌，人生长激素变体hGH-V和催乳素的N-末端序列的约10至约150个连续氨基酸的新型抗血管生成肽及其在抑制血管发生和在诊断涉及胎盘血管化异常的人类怀孕疾病。

4. 发明申请

US20130035289A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF THROMBOSIS-RELATED DISEASES COMPRISING A FRAGMENT OF PROLACTIN (PRL)-GROWTH HORMONE (GH)-PLACENTAL LACTOGEN (PL)-FAMILY PROTEIN 审中-公开
标题翻译：用于治疗包含丙泊酚（PRL） - 生长激素（GH） - 原位乳酸（PL） - 蛋白质蛋白的片段的相关性疾病的药物组合物
公开(公告)号：US20130035289A1
公开(公告)日：2013-02-07
申请号：US13579556
申请日：2011-02-16
申请人： Ingrid Struman , Joseph Martial , Khalid Bajou , Salvino D'Amico
发明人： Ingrid Struman , Joseph Martial , Khalid Bajou , Salvino D'Amico
IPC分类号： A61K38/10 , A61P9/10 , A61P7/02 , A61K38/08 , A61K38/36
CPC分类号： A61K38/2257 , A61K38/22 , A61K38/27
摘要： The present disclosure relates to a pharmaceutical composition for use in the preventive and/or therapeutic treatment of thrombosis-related diseases or conditions relating to high level of plasminogen activator inhibitor 1 (PAI-1) expression, which composition comprises: A) a fragment of a polypeptide or protein of prolactin (PRL)-growth hormone (GH)-placental lactogen (PL)-family and homologous derivatives thereof, which fragment comprises from 6 to 14 consecutive amino acid residues of the amino acid sequence having general formula (I); or B) a peptide or a recombinant protein comprising said peptide, wherein the peptide is from 6 to 50 amino acids in length and has the activity to inhibit PAI-1, said peptide comprising from 6 to 14 consecutive amino acid residues of the amino acid sequence of general formula (I); or C) a polynucleotide encoding said fragment of a polypeptide or protein of A) or said peptide or recombinant protein of B).
摘要翻译：本公开涉及用于预防和/或治疗血栓形成相关疾病或与高水平纤溶酶原激活物抑制剂1（PAI-1）表达相关的病症的药物组合物，该组合物包含：A）催乳素（PRL） - 生长激素（GH） - 胎盘激素（PL）家族及其同源衍生物的多肽或蛋白质，其包含具有通式（I）的氨基酸序列的6至14个连续氨基酸残基， ; 或B）包含所述肽的肽或重组蛋白，其中所述肽长度为6至50个氨基酸并且具有抑制PAI-1的活性，所述肽包含氨基酸的6至14个连续氨基酸残基通式（I）的序列; 或C）编码A）或B）的多肽或蛋白质的所述肽或重组蛋白的所述片段的多核苷酸。

5. 发明授权

US07655626B2 Antiangiogenic peptides 失效
标题翻译：抗血管生成肽
公开(公告)号：US07655626B2
公开(公告)日：2010-02-02
申请号：US11573660
申请日：2005-08-11
申请人： Joseph Martial , Ingrid Struman , Ngoc-Quynh-Nhu Nguyen , Robert Brasseur , Laurence Lins
发明人： Joseph Martial , Ingrid Struman , Ngoc-Quynh-Nhu Nguyen , Robert Brasseur , Laurence Lins
IPC分类号： A61K38/00 , A61K38/10 , A61K38/22 , C07K14/47
CPC分类号： C07K14/005 , A61K38/00 , C07K14/47 , C07K14/4711 , C07K14/57518 , C07K14/57554 , C07K14/61 , C07K14/78 , C12N2740/15022
摘要： The present invention refers to a pharmaceutical composition comprising an isolated antiangiogenic peptide or a recombinant protein comprising the antiangiogenic peptide, wherein the peptide is between 11 and 40 amino acids in length and having antiangiogenic activity, the peptide comprising the amino acid sequence: X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14, wherein X1 is any amino acid residue compatible with forming a helix; X2 is an amino acid residue of: Leu, Ile, Val; X3 is an amino acid residue of: Arg, Lys, His, Ser, Thr; X4 is an amino acid residue of: Ile, Leu, Val; X5 is any amino acid residue compatible with forming a helix; X6 is an amino acid residue of: Leu, Ile, Val; X7 is an amino acid residue of: Leu, Ile, Val, Ser, Thr; X8 is any amino acid residue compatible with forming a helix; X9 is any amino acid residue compatible with forming a helix; X10 is an amino acid residue of: Gln, Glu, Asp, Arg, His, Lys, Asn; X11 is an amino acid residue of: Ser, Thr; X12 is an amino acid residue of: Trp, Tyr, Phe; X13 is an amino acid residue of: Leu, Ile, Val, Asn, Gln; X14 is an amino acid residue of: Glu, Gln, Asp, Asn.
摘要翻译：本发明涉及包含分离的抗血管生成肽或包含抗血管生成肽的重组蛋白质的药物组合物，其中所述肽的长度为11至40个氨基酸且具有抗血管生成活性，所述肽包含氨基酸序列：X1-X2 -X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14，其中X1是与形成螺旋相容的任何氨基酸残基; X2是氨基酸残基：Leu，Ile，Val; X3是氨基酸残基：Arg，Lys，His，Ser，Thr; X4是以下氨基酸残基：Ile，Leu，Val; X5是与形成螺旋相容的任何氨基酸残基; X6是以下氨基酸残基：Leu，Ile，Val; X7是Leu，Ile，Val，Ser，Thr的氨基酸残基; X8是与形成螺旋相容的任何氨基酸残基; X9是与形成螺旋相容的任何氨基酸残基; X10是以下氨基酸残基：Gln，Glu，Asp，Arg，His，Lys，Asn; X11是以下氨基酸残基：Ser，Thr; X12是以下氨基酸残基：Trp，Tyr，Phe; X13是Leu，Ile，Val，Asn，Gln的氨基酸残基; X14是Glu，Gln，Asp，Asn的氨基酸残基。

6. 发明申请

US20080039384A1 Antiangiogenic Peptides 失效
标题翻译：抗血管生成肽
公开(公告)号：US20080039384A1
公开(公告)日：2008-02-14
申请号：US11573660
申请日：2005-08-11
申请人： Joseph Martial , Ingrid Struman , Ngoc-Quynh-Nhu Nguyen , Robert Brasseur , Laurence Lins
发明人： Joseph Martial , Ingrid Struman , Ngoc-Quynh-Nhu Nguyen , Robert Brasseur , Laurence Lins
IPC分类号： A61K38/00 , A61K31/7088 , A61K38/10 , A61K38/16 , A61K38/22 , A61P15/00 , A61P35/00 , C07K14/47 , C07K14/61 , C07K7/08
CPC分类号： C07K14/005 , A61K38/00 , C07K14/47 , C07K14/4711 , C07K14/57518 , C07K14/57554 , C07K14/61 , C07K14/78 , C12N2740/15022
摘要： The present invention refers to a pharmaceutical composition comprising an isolated antiangiogenic peptide or a recombinant protein comprising the antiangiogenic peptide, wherein the peptide is between 11 and 40 amino acids in length and having antiangiogenic activity, the peptide comprising the amino acid sequence: X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14, wherein X1 is any amino acid residue compatible with forming a helix; X2 is an amino acid residue of: Leu, Ile, Val; X3 is an amino acid residue of: Arg, Lys, His, Ser, Thr; X4 is an amino acid residue of: Ile, Leu, Val; X5 is any amino acid residue compatible with forming a helix; X6 is an amino acid residue of: Leu, Ile, Val; X7 is an amino acid residue of: Leu, Ile, Val, Ser, Thr; X8 is any amino acid residue compatible with forming a helix; X9 is any amino acid residue compatible with forming a helix; X10 is an amino acid residue of: Gln, Glu, Asp, Arg, His, Lys, Asn; X11 is an amino acid residue of: Ser, Thr; X12 is an amino acid residue of: Trp, Tyr, Phe; X13 is an amino acid residue of: Leu, Ile, Val, Asn, Gln; X14 is an amino acid residue of: Glu, Gln, Asp, Asn.
摘要翻译：本发明涉及包含分离的抗血管生成肽或包含抗血管生成肽的重组蛋白质的药物组合物，其中所述肽的长度为11至40个氨基酸且具有抗血管生成活性，所述肽包含氨基酸序列：X1-X2 -X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14，其中X1是与形成螺旋相容的任何氨基酸残基; X2是氨基酸残基：Leu，Ile，Val; X3是氨基酸残基：Arg，Lys，His，Ser，Thr; X4是以下氨基酸残基：Ile，Leu，Val; X5是与形成螺旋相容的任何氨基酸残基; X6是以下氨基酸残基：Leu，Ile，Val; X7是Leu，Ile，Val，Ser，Thr的氨基酸残基; X8是与形成螺旋相容的任何氨基酸残基; X9是与形成螺旋相容的任何氨基酸残基; X10是以下氨基酸残基：Gln，Glu，Asp，Arg，His，Lys，Asn; X11是以下氨基酸残基：Ser，Thr; X12是以下氨基酸残基：Trp，Tyr，Phe; X13是Leu，Ile，Val，Asn，Gln的氨基酸残基; X14是Glu，Gln，Asp，Asn的氨基酸残基。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式